<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444222</url>
  </required_header>
  <id_info>
    <org_study_id>s53471</org_study_id>
    <nct_id>NCT01444222</nct_id>
  </id_info>
  <brief_title>Behaviour of Tricuspid Valve Regurgitation in Volume and/or Pressure Loaded Right Heart</brief_title>
  <official_title>Behaviour of Tricuspid Valve Regurgitation in Volume and/or Pressure Loaded Right Heart</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pieter De Meester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Right-sided heart disease has an important impact on the prognosis of patients with valvular&#xD;
      heart disease. Up to now, Tricuspid Valve Regurgitation (TR) and right heart hemodynamics&#xD;
      have not been extensively investigated. However, it is plausible that a significant degree of&#xD;
      TR and the associated volume-overload of the right ventricle cause significant right&#xD;
      ventricular wall stress. Although minor TR generally is well tolerated, major TR can lead to&#xD;
      clinical symptoms, right ventricular dilatation and ultimately right ventricular heart&#xD;
      failure. Up to now, the investigators do not dispose of any tools to diagnose and anticipate&#xD;
      this unfavourable evolution. Nevertheless it is likely that right ventricular failure is&#xD;
      preceded with a subclinical dysfunction of the right ventricle and a possibly reversible&#xD;
      change in contractility of the myocardium.&#xD;
&#xD;
      Recently, new techniques to evaluate the systolic function, the contractility and the&#xD;
      hemodynamics of the heart have become available.&#xD;
&#xD;
      First, this study will help us assessing the feasibility and accuracy of several imaging&#xD;
      modalities in right-sided heart pathology with focus on TR and right heart myocardial&#xD;
      performance.&#xD;
&#xD;
      Second, this study will contribute to a better understanding of the hemodynamic effect of&#xD;
      volume-overload and/or pressure-overload of the right ventricle. It will clarify the&#xD;
      behaviour of TR, the evolution of right ventricular myocardial contractility and dysfunction&#xD;
      during exercise and its impact on exercise capacity. By doing this, discrimination between&#xD;
      well tolerated and ill-tolerated TR will be possible, thus identifying patients who might be&#xD;
      eligible for treatment (medical, corrective, â€¦).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Tricuspid Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Pulmonary Hypertension</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>pulmonic valve stenosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>pulmonic valve homograft</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>pulmonic valve insufficiency</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>atrial septum defect</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Ebstein's anomaly</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>transvalvular right ventricular lead</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        -  Pulmonary Arterial Hypertension&#xD;
&#xD;
          -  Pulmonic Valve Stenosis&#xD;
&#xD;
          -  Pulmonic valve insufficiency&#xD;
&#xD;
          -  Atrium Septum Defect&#xD;
&#xD;
          -  Ebstein's Anomaly&#xD;
&#xD;
          -  Transvalvular RV pacemaker/ shock lead&#xD;
&#xD;
          -  Control&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pulmonary Arterial Hypertension&#xD;
&#xD;
          -  Pulmonic Valve Stenosis&#xD;
&#xD;
          -  Pulmonic valve homograft&#xD;
&#xD;
          -  Pulmonic valve insufficiency&#xD;
&#xD;
          -  Atrium Septum Defect&#xD;
&#xD;
          -  Ebstein's Anomaly&#xD;
&#xD;
          -  Transvalvular RV pacemaker/ shock lead&#xD;
&#xD;
          -  Control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 16 years&#xD;
&#xD;
          -  not fit for bicycle testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Budts, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pieter De Meester, MD</last_name>
    <phone>016342371</phone>
    <phone_ext>0032</phone_ext>
    <email>pieter.demeester@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZLeuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Pieter De Meester, MD</last_name>
      <phone>016342371</phone>
      <phone_ext>0032</phone_ext>
      <email>pieter.demeester@uzleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>September 27, 2011</study_first_submitted>
  <study_first_submitted_qc>September 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2011</study_first_posted>
  <last_update_submitted>September 30, 2011</last_update_submitted>
  <last_update_submitted_qc>September 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Pieter De Meester</investigator_full_name>
    <investigator_title>research fellow</investigator_title>
  </responsible_party>
  <keyword>Myocardial contractility</keyword>
  <keyword>Quantification of regurgitant flow</keyword>
  <keyword>exercise capacity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

